Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit

Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012
                              Asian Lupus Summit

PR Newswire

HAYWARD, Calif., Nov. 28, 2012

HAYWARD, Calif., Nov. 28, 2012 /PRNewswire/ --Anthera Pharmaceuticals, Inc.
(Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious
diseases associated with inflammation and autoimmune disorders, today
announced additional data from its Phase 2b PEARL-SC study was presented in a
poster at the 2012 Asian Lupus Summit. The poster entitled "The Subcutaneous
BAFF Inhibitor, Blisibimod, Significantly Reduces Proteinuria in Subjects with
Moderate-to-Severe Systemic Lupus Erythematosis," is being displayed at the
conference today Wednesday, November 28, 2012.

In addition to the effects seen in the modified intent to treat population in
the PEARL-SC study, which was presented at the recent 2012 ACR/ARHP
conference, the poster highlights additional data related to the effect of
blisibimod on renal disease in lupus. Both the pooled blisibimod treatment
group and the 200 mg weekly blisibimod treatment group showed a statistically
significant treatment reduction in proteinuria. 

"These data provide further rationale for broadening the CHABLIS-SC2 study
population to include both patients with severe disease and patients suffering
from lupus nephritis," said Colin Hislop, MD, Anthera's Senior Vice President
and Chief Medical Officer. "These data will also guide our plans to pursue
studies in IgA nephropathy and other renal diseases that involve B-cells."

The poster will be available on www.anthera.com.

About Blisibimod and PEARL-SC

BAFF has been associated with a wide range of B-cell-mediated autoimmune
diseases, including systemic lupus erythematosus, vasculitis, IgA nephropathy,
immune thrombocytopenic purpura and others. Multiple clinical studies with
other BAFF antagonists recently have reported on BAFF's potential positive
role in treating lupus and rheumatoid arthritis. Anthera is advancing its
development of blisibimod, a broad inhibitor of BAFF, to expand its potential
clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein
called a peptibody and is distinct from an antibody. Anthera owns worldwide
rights to blisibimod in all potential indications.The PEARL-SC Phase 2 study
was designed as a randomized, double-blind, placebo-controlled, dose-ranging
superiority trial to evaluate the safety, tolerability and efficacy of
blisibimod plus standard of care, versus placebo plus standard of care.A
total of 547 patients with active SLE were randomized to receive one of three
different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200
mg monthly) administered subcutaneously over a minimum 24-week treatment
period, in addition to standard-of-care therapy. The study was conducted at
multiple centers worldwide.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing products to treat serious diseases associated with
inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or
other non-historical matters, including statements that are preceded by,
followed by, or that include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," "project," or similar statements, are
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are based on Anthera's expectations as of the date of this press
release and are subject to certain risks and uncertainties that could cause
actual results to differ materially as set forth in Anthera's public filings
with the SEC, including Anthera's Annual Report on Form 10-K for the year
ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter
ended September 30, 2012.Anthera disclaims any intent or obligation to update
any forward-looking statements, whether because of new information, future
events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or
510.856.5586.

SOURCE Anthera Pharmaceuticals, Inc.

Website: http://www.anthera.com
 
Press spacebar to pause and continue. Press esc to stop.